X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Fighting variants of COVID-19

By Richard Moscicki, M.D.  |    February 22, 2021
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. To date, two...   Read More

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing

By Tom Wilbur  |    February 12, 2021
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and...   Read More

Lessons learned from COVID-19: The way we develop new medicines is changing

By Richard Moscicki, M.D.  |    February 10, 2021
The COVID-19 pandemic has affected nearly every aspect of society, including the way scientists conduct the testing of medicines.   Read More

2020 FDA approvals show innovation despite COVID-19 pandemic challenges

By Andrew Powaleny  |    January 26, 2021
A new report from the U.S. Food and Drug Administration (FDA) notes that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year. These figures are in addition to...   Read More

ICYMI: Cancer death rate continues decline due to advances in treatment

By Andrew Powaleny  |    January 19, 2021
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Guest Post: Bringing our best to the fight against COVID-19

By Guest Contributor  |    December 3, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D

By Nicole Longo  |    November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...   Read More

Understanding the emergency use authorization process for COVID-19 vaccines

By Richard Moscicki, M.D.  |    November 12, 2020
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop safe and effective vaccines to prevent infection, as well...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates